Bortezomib (BTZ) and dasatinib (DA) are two substantial anti-cancer agents with side effects on the human body. In this research, we fabricated a novel electrochemical sensor modified by CuFe2O4/ SmVO4 nanocomposite and 1-ethyl-3-methylimidazolium chloride (1E3MC) as an ionic liquid (IL) ( CuFe2O4/SmVO4/IL/CPE) for coinciding investigation of BTZ and DA for the first time. The CuFe2O4/ SmVO4 synthesized were determined and certified through field-emission scanning electron microscopy (FE-SEM), energy diffraction X-ray (EDX), and X-ray diffraction (XRD). The capability of the sensor was investigated by different electrochemical techniques such as cyclic voltammetry (CV), chronoamperometry (CHA), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS). The attained data showed that the oxidation signal of bortezomib and dasatinib promoted as an innovative electrochemical sensor. After optimization of the conditions using this sensor at pH 7.0, the oxidation signal of bortezomib and dasatinib showed to be linear with drug concentrations in the range of 0.09–90 μM and 100–500 μM with a detection limit of 5.4 nM and 7.0 μM, respectively, using differential pulse voltammetry method. The values of D and electro-transfer coefficient (α) achieved 2.5 × 10− 5 cm2 s− 1 and 0.99, respectively. The proposed electrochemical sensor exhibited acceptable selectivity and sensitivity for simultaneous detection of bortezomib and dasatinib in pharmaceutical and biological samples.

Determination of bortezomib and dasatinib anticancer drugs in real samples using an electrochemical sensor modified with new CuFe2O4SmVO4ionic liquid nanocomposite
    Abstract
    1 Introduction
    2 Experimental
        2.1 Reagents and apparatus
        2.2 Synthesis of CuFe2O4SmVO4
        2.3 Fabrication of CuFe2O4SmVO4ILCPE
        2.4 Real samples’ preparation
    3 Results and discussion
        3.1 Characterization of CuFe2O4SmVO4
        3.2 Electrochemical behavior of bortezomib at a surface of CuFe2O4SmVO4ILCPE
        3.3 Calibration plot and limit of detection
        3.4 Simultaneous determination of BTZ and DA
        3.5 Selectivity investigation
        3.6 Reproducibility and stability investigation
        3.7 Bortezomib and dasatinib analysis in real samples
    4 Conclusion
    Acknowledgements 
    References

• Abbas Jafari‑Kashi(Department of Analytical Chemistry, Faculty of Chemistry, University of Kashan, Kashan, Islamic Republic of Iran)
• Mehdi Shabani‑Nooshabadi(Department of Analytical Chemistry, Faculty of Chemistry, University of Kashan, Kashan, Islamic Republic of Iran, Institute of Nano Science and Nano Technology, University of Kashan, Kashan, Islamic Republic of Iran) Corresponding author
• Hossain‑Ali Rafiee‑Pour(Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Islamic Republic of Iran)